Stonegate Investment Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$42.6M Sell
55,896
-1,677
-3% -$1.25M 0.99% 34
2025
Q2
$44.9M Buy
57,573
+834
+1% +$648K 1.13% 32
2025
Q1
$46.9M Buy
56,739
+456
+0.8% +$379K 1.25% 31
2024
Q4
$43.5M Sell
56,283
-716
-1% -$593K 1.16% 32
2024
Q3
$50.5M Buy
56,999
+862
+2% +$775K 1.33% 30
2024
Q2
$50.8M Buy
56,137
+2,342
+4% +$1.87M 1.47% 27
2024
Q1
$41.9M Sell
53,795
-12,923
-19% -$9.2M 1.31% 30
2023
Q4
$38.9M Sell
66,718
-963
-1% -$562K 1.29% 32
2023
Q3
$36.4M Buy
67,681
+537
+0.8% +$277K 1.32% 30
2023
Q2
$31.5M Buy
67,144
+88
+0.1% +$36.9K 1.12% 31
2023
Q1
$23M Buy
67,056
+63,517
+1,795% +$21.4M 0.86% 33
2022
Q4
$1.29M Buy
3,539
+254
+8% +$90.1K 0.06% 122
2022
Q3
$1.06M Buy
3,285
+4
+0.1% +$1.27K 0.05% 129
2022
Q2
$1.06M Buy
3,281
+1,199
+58% +$360K 0.05% 135
2022
Q1
$596K Buy
2,082
+290
+16% +$74.6K 0.02% 159
2021
Q4
$495K Buy
+1,792
New +$454K 0.02% 176

Other funds holding LLY

Stonegate Investment Group's LLY Position: Q3 2025 in Review

Stonegate Investment Group reduced its Eli Lilly (LLY) stake by 2.9% in Q3 2025, selling an estimated $1.25M and leaving 55,896 shares worth $42.6M. The position accounts for 0.99% of the portfolio, ranked #34.

Stonegate Investment Group first reported a position in LLY in Q4 2021 and has held it in 16 quarters since. The position peaked at $50.8M in Q2 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

  • Stonegate Investment Group held 55,896 shares of Eli Lilly worth $42.6M as of Q3 2025.
  • Stonegate Investment Group sold 1,677 Eli Lilly shares in Q3 2025, an estimated $1.25M.
  • Eli Lilly made up 0.99% of Stonegate Investment Group's portfolio in Q3 2025, its #34 holding.
  • Stonegate Investment Group first reported a position in Eli Lilly in Q4 2021 and has held it in 16 quarters since.
  • Stonegate Investment Group's Eli Lilly position peaked at $50.8M in Q2 2024.
  • 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Stonegate Investment Group's 13F filing for Q3 2025, filed 3 Nov 2025.